Laboratorio G. Lanzani, Bergamo Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2013
NCT02012153
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Laboratorio G. Lanzani, Bergamo, Italy | Laboratorio G.Lanzani, Bergamo, Italy

Active Ingredients

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cells (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Failure, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 1